U.S. Healthtech Stock News

The sudden progress toward a US Iran peace deal and the potential reopening of the Strait of Hormuz has pulled oil prices lower and shifted attention to companies that are sensitive to fuel costs and global stability. For investors, this is a moment to reassess which stocks might benefit if cheaper energy and reduced geopolitical risk persist, and which could lose some pricing power. This article highlights 3 stocks from a Global Airlines and Travel screener that appear positively exposed to...

The Defiance 2X Space ETF (SPCL) repositioned around SpaceX before its debut and gained 56% before the ETF entered a trading halt.

In recent months, Corvus Pharmaceuticals reported encouraging Phase 1 results for its oral ITK inhibitor soquelitinib in atopic dermatitis, showing early efficacy signals alongside a clean safety profile and extending its cash runway into the second quarter of 2028. These developments, coupled with upbeat coverage from investment commentators highlighting soquelitinib’s potential to compete in immunology and attract larger partners, have drawn fresh attention to Corvus’s pipeline and funding...

McCann, an Omnicom Group (NYSE:OMC) subsidiary, released a new global study on brand relevance and growth strategies. The research introduces the "Upward Class," a large and influential consumer group shaping how brands grow worldwide. The findings highlight changing expectations for how brands connect with this audience and maintain relevance. For Omnicom Group, a global advertising and marketing services company, this kind of research sits close to the core of its business. As clients...

Earlier this week, U.S. self-defense strikes on Iran heightened Middle East tensions, increasing concerns about potential disruptions to Iranian oil supply and shifting attention to alternative producers. This backdrop has put U.S. shale operators such as HighPeak Energy in sharper focus as potential contributors to any future global supply gaps, without necessarily altering the company’s longer-term fundamentals. Next, we’ll examine how heightened Middle East supply risk, and HighPeak’s...

Energy stocks are again in the spotlight as investors watch headlines about a possible U.S. Iran deal, G7 talks on wars and trade, and fresh debates on AI and global security. These stories are not just politics; they can influence oil supply routes, risk premiums, and sentiment toward large producers and refiners. For investors, that mix can create pockets of opportunity and pockets of risk. This article highlights 3 large energy stocks from our screener that look particularly exposed to...

Recent analyst upgrades for Relay Therapeutics (RLAY) focus on early clinical data for its drug candidate zovegalisib. Initial results in PIK3CA-driven vascular anomalies, particularly in heavily treated patients, have drawn increased attention to the stock. See our latest analysis for Relay Therapeutics. The recent enthusiasm around zovegalisib comes on top of strong price momentum, with a 1-month share price return of 21.39%, a 3-month share price return of 46.20% and a year-to-date share...

Earlier this month, Diehl Defence announced it had signed a Memorandum of Understanding with Spire Global at the ILA Berlin Airshow 2026 to explore collaboration on satellite-based intelligence and early warning against ballistic and hypersonic missiles, drawing on Spire’s RF detection and analytics capabilities. This collaboration framework, paired with Spire’s new Munich facility capable of producing up to 100 satellites per year, highlights how the company is positioning itself as a...

Tronox Holdings has released its 2025 sustainability report, confirming it exceeded its environmental and safety targets and permanently closed its Fuzhou TiO₂ plant in China to better align operations with market conditions. The report links these environmental gains and footprint changes with progress in Tronox’s rare earths program, underscoring how sustainability efforts are being tied directly to future product and market opportunities. Next, we’ll examine how Tronox’s progress in rare...

York Space Systems (YSS) saw its stock drop more than 16% on June 12, 2026, after investors reacted to the planned SpaceX IPO and ongoing concerns around York’s profitability and sector volatility. See our latest analysis for York Space Systems. That sharp 1 day share price return of down 17.9% sits against a 30 day share price return of 15.3% and a 90 day share price return of 39.7%. This suggests recent momentum had been building before the latest pullback as investors weighed York’s...

H2O America recently announced that executive Kristen Johnson will depart the company without cause, effective 3 July 2026, with severance provided under her employment agreement. Alongside this leadership change, H2O America has extended its 58-year dividend growth streak with a 4.8% quarterly increase and reaffirmed its 2026 earnings guidance. Next, we’ll examine how Johnson’s departure and the continued dividend growth track record may influence H2O America’s broader investment...

Bolt, Pony.ai, and Stellantis recently launched an autonomous mobility pilot in Luxembourg to test Pony.ai’s seventh-generation robotaxi on Stellantis’ L4-Ready midsize vans using Bolt’s ride-hailing platform. The project highlights Luxembourg’s supportive regulatory framework as a proving ground for validating Pony.ai’s autonomous driving technology and readiness for future European deployment. Next, we will examine how this European pilot, especially testing seventh-generation autonomous...

We wouldn't blame Expedia Group, Inc. ( NASDAQ:EXPE ) shareholders if they were a little worried about the fact that...

Ooma, Inc.'s ( NYSE:OOMA ) earnings announcement last week was disappointing for investors, despite the decent profit...

We wouldn't blame NRC Health ( NASDAQ:NRC ) shareholders if they were a little worried about the fact that Michael...

With war in Iran disrupting oil supplies, energy prices jumping and inflation back at a three year high, the mood in markets has shifted fast. Higher U.S. Treasury yields and talk of fresh Federal Reserve rate hikes are putting pressure on richly priced growth stories, while investors pay closer attention to cash flow and balance sheet strength. Dividend growth stocks with solid financial footing can look appealing in this kind of backdrop, but not all are affected in the same way. This...

Kennedy-Wilson Holdings (KW) has attracted fresh attention after recent trading, with the stock last closing at $10.93. For investors, that price stands in the context of mixed recent returns and sizeable exposure to global real estate. See our latest analysis for Kennedy-Wilson Holdings. Recent trading has been relatively muted, with a 1 day share price return of 0.09% and a 30 day share price return of 0.91%. However, a 13.38% year to date share price return sits alongside a 1 year total...

Some The J. M. Smucker Company ( NYSE:SJM ) shareholders may be a little concerned to see that the Chief Legal Officer...

Some Gen Digital Inc. ( NASDAQ:GEN ) shareholders may be a little concerned to see that the Director, Ondrej Vlcek...

The recent 17% drop in CervoMed Inc.'s ( NASDAQ:CRVO ) stock could come as a blow to insiders who purchased US$455.1k...

We wouldn't blame Centene Corporation ( NYSE:CNC ) shareholders if they were a little worried about the fact that...

SpaceX’s record US$75b IPO and US$2t market cap have grabbed headlines, but the ripple effects may matter more for you as an investor. Fresh enthusiasm for mega-IPOs and high-growth stories is colliding with questions about rich valuations and business risk. That mix of optimism and caution is now spilling over into other recently listed large caps that could one day qualify for major indices. This article highlights 3 stocks from our Index Inclusion Beneficiaries screener that are especially...

Structure Therapeutics (GPCR) drew attention after publishing Phase 2b ACCESS trial data for its oral GLP-1 candidate aleniglipron in Nature Medicine, alongside a detailed presentation at the American Diabetes Association’s 86th Scientific Sessions. See our latest analysis for Structure Therapeutics. The latest data release has arrived against a mixed price backdrop, with the stock at US$42.93 after a strong 7 day share price return of 14.24%. This contrasts with a weaker 90 day share price...

Recent price performance and business mix Icahn Enterprises (IEP) has seen its unit price decline about 10% over the past month and about 5% over the past 3 months, drawing attention to how its diversified operations are currently valued. The partnership spans multiple businesses, including investment funds, energy refining and renewables, automotive services and parts, food packaging, real estate, home fashion and pharma. As a result, the stock reflects a mix of cyclical and defensive...